DOCSLIB.ORG

UCLA Electronic Theses and Dissertations

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
UCLA Electronic Theses and Dissertations UCLA UCLA Electronic Theses and Dissertations Title Disease-specific differences in glycosylation of mouse and human skeletal muscle Permalink https://escholarship.org/uc/item/73v762qp Author McMorran, Brian James Publication Date 2017 Peer reviewed|Thesis/dissertation eScholarship.org Powered by the California Digital Library University of California UNIVERSITY OF CALIFORNIA Los Angeles Disease-specific differences in glycosylation of mouse and human skeletal muscle A dissertation submitted in partial satisfaction of the requirements for the Degree of Philosophy in Cellular and Molecular Pathology by Brian James McMorran 2017 © Copyright by Brian James McMorran 2017 ABSTRACT OF THE DISSERTATION Disease-specific differences in glycosylation of mouse and human skeletal muscle by Brian James McMorran Doctor of Philosophy in Cellular and Molecular Pathology University of California, Los Angeles, 2017 Professor Linda G. Baum, Chair Proper glycosylation of proteins at the muscle cell membrane, or sarcolemma, is critical for proper muscle function. The laminin receptor alpha-dystroglycan (α-DG) is heavily glycosylated and mutations in 24 genes involved in proper α-DG glycosylation have been identified as causing various forms of congenital muscular dystrophy. While work over the past decade has elucidated the structure bound by laminin and the enzymes required for its creation, very little is known about muscle glycosylation outside of α-DG glycosylation. The modification of glycan structures with terminal GalNAc residues at the rodent neuromuscular junction (NMJ) has remained the focus of work in mouse muscle glycosylation, while qualitative lectin histochemistry studies performed three decades ago represent the majority of human muscle glycosylation research. This thesis quantifies differentiation-, species-, and disease-specific differences in mouse and human skeletal muscle glycosylation. Following differentiation of mouse myotubes, increased binding was found of lectins specific for GalNAc and O-glycans. Additionally, ii analysis of binding preferences of four GalNAc-specific lectins, which historically have been used to identify the rodent NMJ, identified differences in the glycan types bound on distinct glycoproteins by each lectin. Following differentiation of human myotubes, specific increases in binding of high mannose N-glycan specific lectin NPA, asialo core 1 O-glycan specific lectin PNA, α2,3-linked sialic acid specific lectin MAA-II and GalNAc specific lectin WFA were observed. Disease-specific differences in binding of NPA, Jac (sialylated core 1 O-glycans), TJA-I (α2,3-linked sialic acid) and WFA were observed quantitatively when comparing binding to healthy and dystrophic myotubes as well as qualitatively via lectin staining of healthy and dystrophic human skeletal muscle tissue sections. This work provides the first quantitative characterization of mouse and human muscle glycosylation, identifies lectin biomarkers for differentiation-, species-, and disease-specific differences in mouse and human muscle glycosylation, and lays the groundwork for future studies which further our understanding of the relationship between proper muscle glycosylation and muscle function. iii The dissertation of Brian James McMorran is approved. M. Carrie Miceli Stanley F. Nelson Michael A. Teitell Linda G. Baum, Committee Chair University of California, Los Angeles 2017 iv “And now that you don’t have to be perfect, you can be good” -John Steinbeck, East of Eden This work is dedicated to Ryan, without whom I would still be seeking perfect. v TABLE OF CONTENTS LIST OF FIGURES………………………………………………………………………………vii LIST OF TABLES.………………………………………………………………………..……...ix LIST OF ABBREVIATIONS……………………………………………………………………..x ACKNOWLEDGMENTS……………….…………………………..…………………………..xii VITA………………………………………………………………………...………...………....xv CHAPTER 1: Introduction………………………………………………………………..1 References……………………………………………………………..…21 CHAPTER 2: The potential of sarcospan in adhesion complex replacement therapeutics for the treatment of muscular dystrophy……….…...………35 References……………………………………………………………..…48 CHAPTER 3: Differentiation-related glycan epitopes identify discrete domains of the muscle glycocalyx…………….……………………….…56 References……………………………………………………………..…67 CHAPTER 4: Lectin binding characterizes the healthy human skeletal muscle glycophenotype and identifies disease specific changes in dystrophic muscle…………………………………………….………..…70 References……………………………………………………..………..103 CHAPTER 5: Conclusions and future directions……………………………..……..…111 References……………………………………………………………....118 APPENDIX A: C2C12 myoblast and myotube glycotranscript expression…….……..…121 APPENDIX B: Glycan structures preferentially bound by nominally GalNAc- specific lectins: WFA, VVA-B4, SBA and DBA………….……………128 APPENDIX C: Healthy and dystrophic, human myoblast and myotube glycotranscript expression…………………………………….……...…131 vi LIST OF FIGURES CHAPTER 1 Figure 1-1: Mammalian glycosylation………………………………………………………...…15 Figure 1-2: Major sarcolemmal adhesion complexes………….…………………………………17 Figure 1-3: α-DG O-mannosylation……………………………………………………………...19 CHAPTER 2 Figure 2-1: UGC- and α7β1 integrin-mediated replacement therapy for the DGC in DMD…...….40 Figure 2-2: Glycosylation of α-DG…………………………………………….…………………41 Figure 2-3: Effects of SSPN overexpression in mdx mice on the cell surface protein expression and processing and possible outcomes of truncated dystrophin within the cell………………………………………………………………………..45 CHAPTER 3 Figure 3-1: The DGC, UGC and α7-integrin are not requisite for binding of GalNAc- specific lectins……………………………………………………………………….59 Figure 3-2: Distinct increases in binding of GalNAc-specific lectins following differentiation of C2C12 myotubes………….………………………………………60 Figure 3-3: GalNAc-specific lectins precipitate different glycoproteins………………………...61 Figure 3-4: Reduced expression of β4Galnt3, β3Galnt2, and Neu2 drive distinct changes in binding of GalNAc-specific lectins…………………………….…………..……..62 Figure 3-5: Complex N-glycans are required for binding of WFA……………………………...63 CHAPTER 4 Figure 4-1: Changes in cell surface glycosylation following differentiation of primary and immortalized healthy human myotubes………………………………..93 Figure 4-2: Disease-specific changes in lectin binding to human skeletal muscle cells…………..95 vii Figure 4-3: Different lectins precipitate different glycoproteins from healthy and dystrophic human myotubes…………………………………………………….97 Figure 4-4: Disease-specific differences in O-glycan and sialic acid-specific lectin binding to human skeletal muscle……………………………………………..99 Figure 4-5: Lectin binding to frozen versus fixed skeletal muscle………………………..……101 viii LIST OF TABLES CHAPTER 3 Table 3-1: Panel of lectins with varying specificities utilized to characterize changes in muscle glycosylation following differentiation of C2C12 myotubes………….……60 Table 3-2: Twenty-three glycosyltransferase and glycosidase transcripts upregulated following C2C12 differentiation and identified via glycotranscriptome analysis….…61 Table 3-3: Seventeen glycans with terminal GalNAc residues on CFG glycan arrays were identified as binding at least one of the four GalNAc-specific lectins…………...64 CHAPTER 4 Table 4-1: Primary and immortalized, healthy and dystrophic human myoblast cell sources …....91 Table 4-2: Panel of lectins with varying glycan structure specificities ………………………..….92 ix LIST OF ABBREVIATIONS AAV- adeno-associated virus FDA- Food and Drug Administration AChR- acetylcholine receptor FFPE- formalin-fixed, paraformaldehyde α-BTX- alpha bungarotoxin embedded α-DG- alpha-dystroglycan FKTN- fukutin B3GALNT2- β1,3-N- FKRP- fukutin-related protein Acetylgalactosaminyltransferase 2 FMD- Fukuyama muscular dystrophy B4GALNT2- β1,4-N- GAG- glycosaminoglycan Acetylgalactosaminyltransferase 2 Gal-1- galectin-1 B4GAT1- β1,4-glucuronyltransferase 1 GalNAc- N-acetylgalactosamine BMD- Becker muscular dystrophy GlcA- glucuronic acid β-DG- beta-dystroglycan GlcNAc- N-acetylglucosamine β-Xyl- beta-xylose GPI- glycosylphosphatidylinositol cGMP- cyclic guanosine monophosphate GTDC2- glycosyltransferase-like domain CMAH- cytidine monophosphate acid containing hydrolase HPA- Helix pomatia agglutinin CMD- congenital muscular dystrophy HSMC- human skeletal muscle cells ConA- Concanavalin A Hsp- heat shock proteins DBA- Dolichos biflorus agglutinin HTS- high throughput screen DGC- dystrophin-glycoprotein complex iDRMs- inducible, directly reprogrammable DMD- Duchenne muscular dystrophy myotubes DMNJ- deoxymannojirimycin ILK- integrin-linked kinase ECM- extracellular matrix x ISPD- isoprenoid synthase domain PNGaseF- Peptide-N-glycosidase F containing POMT1/2- Protein O-Mannosyltransferases Jac- jacalin 1 and 2 LARGE1/2- like- POMGNT1/2- Protein O-Linked Mannose acetylglucosaminyltransferase 1/2 N-Acetylglucosaminyltransferase 1/2 LG- laminin globular RboP- ribitol-phosphate LGMD- limb-girdle muscular dystrophy RCA 120- Ricinus communis agglutinin I MAA-II- Maackia amurensis agglutinin-II RXYLT1- Ribitol β-1,2 Xylosyltransferase MGAT5b- Mannosyl (α1,6)-Glycoprotein 1 β1,6-N-Acetyl-Glucosaminyltransferase SA-HRP- streptavidin-horseradish MTJ- myotendinous junction peroxidase Neu2- sialidase/neuraminidase 2 SBA- soybean agglutinin NeuAc- N-acetylneuraminic acid SG- sarcoglycan NeuGc- N-glycolylneuraminic acid SNA- Sambucus nigra agglutinin NMJ- neuromuscular junction SSPN- sarcospan nNOS- neuronal nitric oxide synthase TJA-I- Tricosanthes japonica agglutinin-I NO- nitric oxide TMEM5- transmembrane protein 5 NP-40- Nonidet
Load more

Recommended publications
  • Environmental Influences on Endothelial Gene Expression
    ENDOTHELIAL CELL GENE EXPRESSION John Matthew Jeff Herbert Supervisors: Prof. Roy Bicknell and Dr. Victoria Heath PhD thesis University of Birmingham August 2012 University of Birmingham Research Archive e-theses repository This unpublished thesis/dissertation is copyright of the author and/or third parties. The intellectual property rights of the author or third parties in respect of this work are as defined by The Copyright Designs and Patents Act 1988 or as modified by any successor legislation. Any use made of information contained in this thesis/dissertation must be in accordance with that legislation and must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the permission of the copyright holder. ABSTRACT Tumour angiogenesis is a vital process in the pathology of tumour development and metastasis. Targeting markers of tumour endothelium provide a means of targeted destruction of a tumours oxygen and nutrient supply via destruction of tumour vasculature, which in turn ultimately leads to beneficial consequences to patients. Although current anti -angiogenic and vascular targeting strategies help patients, more potently in combination with chemo therapy, there is still a need for more tumour endothelial marker discoveries as current treatments have cardiovascular and other side effects. For the first time, the analyses of in-vivo biotinylation of an embryonic system is performed to obtain putative vascular targets. Also for the first time, deep sequencing is applied to freshly isolated tumour and normal endothelial cells from lung, colon and bladder tissues for the identification of pan-vascular-targets. Integration of the proteomic, deep sequencing, public cDNA libraries and microarrays, delivers 5,892 putative vascular targets to the science community.
    [Show full text]
  • Contig Protein Description Symbol Anterior Posterior Ratio
    Table S2. List of proteins detected in anterior and posterior intestine pooled samples. Data on protein expression are mean ± SEM of 4 pools fed the experimental diets. The number of the contig in the Sea Bream Database (http://nutrigroup-iats.org/seabreamdb) is indicated. Contig Protein Description Symbol Anterior Posterior Ratio Ant/Pos C2_6629 1,4-alpha-glucan-branching enzyme GBE1 0.88±0.1 0.91±0.03 0.98 C2_4764 116 kDa U5 small nuclear ribonucleoprotein component EFTUD2 0.74±0.09 0.71±0.05 1.03 C2_299 14-3-3 protein beta/alpha-1 YWHAB 1.45±0.23 2.18±0.09 0.67 C2_268 14-3-3 protein epsilon YWHAE 1.28±0.2 2.01±0.13 0.63 C2_2474 14-3-3 protein gamma-1 YWHAG 1.8±0.41 2.72±0.09 0.66 C2_1017 14-3-3 protein zeta YWHAZ 1.33±0.14 4.41±0.38 0.30 C2_34474 14-3-3-like protein 2 YWHAQ 1.3±0.11 1.85±0.13 0.70 C2_4902 17-beta-hydroxysteroid dehydrogenase 14 HSD17B14 0.93±0.05 2.33±0.09 0.40 C2_3100 1-acylglycerol-3-phosphate O-acyltransferase ABHD5 ABHD5 0.85±0.07 0.78±0.13 1.10 C2_15440 1-phosphatidylinositol phosphodiesterase PLCD1 0.65±0.12 0.4±0.06 1.65 C2_12986 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase delta-1 PLCD1 0.76±0.08 1.15±0.16 0.66 C2_4412 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase gamma-2 PLCG2 1.13±0.08 2.08±0.27 0.54 C2_3170 2,4-dienoyl-CoA reductase, mitochondrial DECR1 1.16±0.1 0.83±0.03 1.39 C2_1520 26S protease regulatory subunit 10B PSMC6 1.37±0.21 1.43±0.04 0.96 C2_4264 26S protease regulatory subunit 4 PSMC1 1.2±0.2 1.78±0.08 0.68 C2_1666 26S protease regulatory subunit 6A PSMC3 1.44±0.24 1.61±0.08
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Review Sialic Acid-Specific Lectins: Occurrence, Specificity and Function
    Cell. Mol. Life Sci. 63 (2006) 1331–1354 1420-682X/06/121331-24 DOI 10.1007/s00018-005-5589-y Cellular and Molecular Life Sciences © Birkhäuser Verlag, Basel, 2006 Review Sialic acid-specific lectins: occurrence, specificity and function F. Lehmanna, *, E. Tiralongob and J. Tiralongoa a Institute for Glycomics, Griffith University (Gold Coast Campus), PMB 50 Gold Coast Mail Centre Australia 9726 (Australia), Fax: +61 7 5552 8098; e-mail: [email protected] b School of Pharmacy, Griffith University (Gold Coast Campus), PMB 50 Gold Coast Mail Centre Australia 9726 (Australia) Received 13 December 2005; received after revision 9 February 2006; accepted 15 February 2006 Online First 5 April 2006 Abstract. Sialic acids consist of a family of acidic nine- through specific interactions with lectins, a family of carbon sugars that are typically located at the terminal po- proteins that recognise and bind sugars. This review will sitions of a variety of glycoconjugates. Naturally occur- present a detailed overview of our current knowledge re- ring sialic acids show an immense diversity of structure, garding the occurrence, specificity and function of sialic and this reflects their involvement in a variety of biologi- acid-specific lectins, particularly those that occur in vi- cally important processes. One such process involves the ruses, bacteria and non-vertebrate eukaryotes. direct participation of sialic acids in recognition events Keywords. Sialic acid, lectin, sialoglycoconjugate, sialic acid-specific lectin, adhesin, infectious disease, immunology. Introduction [1, 2]. The largest structural variations of naturally occurring Sia are at carbon 5, which can be substituted with either an Sialic acids (Sia) are a family of nine-carbon a-keto acids acetamido, hydroxyacetamido or hydroxyl moiety to form (Fig.
    [Show full text]
  • Molecular Mechanisms Regulating Copper Balance in Human Cells
    MOLECULAR MECHANISMS REGULATING COPPER BALANCE IN HUMAN CELLS by Nesrin M. Hasan A dissertation submitted to Johns Hopkins University in conformity with the requirements for the degree of Doctor of Philosophy Baltimore, Maryland August 2014 ©2014 Nesrin M. Hasan All Rights Reserved Intended to be blank ii ABSTRACT Precise copper balance is essential for normal growth, differentiation, and function of human cells. Loss of copper homeostasis is associated with heart hypertrophy, liver failure, neuronal de-myelination and other pathologies. The copper-transporting ATPases ATP7A and ATP7B maintain cellular copper homeostasis. In response to copper elevation, they traffic from the trans-Golgi network (TGN) to vesicles where they sequester excess copper for further export. The mechanisms regulating activity and trafficking of ATP7A/7B are not well understood. Our studies focused on determining the role of kinase-mediated phosphorylation in copper induced trafficking of ATP7B, and identifying and characterizing novel regulators of ATP7A. We have shown that Ser- 340/341 region of ATP7B plays an important role in interactions between the N-terminus and the nucleotide-binding domain and that mutations in these residues result in vesicular localization of the protein independent of the intracellular copper levels. We have determined that structural changes that alter the inter-domain interactions initiate exit of ATP7B from the TGN and that the role of copper-induced kinase-mediated hyperphosphorylation might be to maintain an open interface between the domains of ATP7B. In a separate study, seven proteins were identified, which upon knockdown result in increased intracellular copper levels. We performed an initial characterization of the knock-downs and obtained intriguing results indicating that these proteins regulate ATP7A protein levels, post-translational modifications, and copper-dependent trafficking.
    [Show full text]
  • Biological Models of Colorectal Cancer Metastasis and Tumor Suppression
    BIOLOGICAL MODELS OF COLORECTAL CANCER METASTASIS AND TUMOR SUPPRESSION PROVIDE MECHANISTIC INSIGHTS TO GUIDE PERSONALIZED CARE OF THE COLORECTAL CANCER PATIENT By Jesse Joshua Smith Dissertation Submitted to the Faculty of the Graduate School of Vanderbilt University In partial fulfillment of the requirements For the degree of DOCTOR OF PHILOSOPHY In Cell and Developmental Biology May, 2010 Nashville, Tennessee Approved: Professor R. Daniel Beauchamp Professor Robert J. Coffey Professor Mark deCaestecker Professor Ethan Lee Professor Steven K. Hanks Copyright 2010 by Jesse Joshua Smith All Rights Reserved To my grandparents, Gladys and A.L. Lyth and Juanda Ruth and J.E. Smith, fully supportive and never in doubt. To my amazing and enduring parents, Rebecca Lyth and Jesse E. Smith, Jr., always there for me. .my sure foundation. To Jeannine, Bill and Reagan for encouragement, patience, love, trust and a solid backing. To Granny George and Shawn for loving support and care. And To my beautiful wife, Kelly, My heart, soul and great love, Infinitely supportive, patient and graceful. ii ACKNOWLEDGEMENTS This work would not have been possible without the financial support of the Vanderbilt Medical Scientist Training Program through the Clinical and Translational Science Award (Clinical Investigator Track), the Society of University Surgeons-Ethicon Scholarship Fund and the Surgical Oncology T32 grant and the Vanderbilt Medical Center Section of Surgical Sciences and the Department of Surgical Oncology. I am especially indebted to Drs. R. Daniel Beauchamp, Chairman of the Section of Surgical Sciences, Dr. James R. Goldenring, Vice Chairman of Research of the Department of Surgery, Dr. Naji N.
    [Show full text]
  • UGT1A6 (NM 205862) Human Recombinant Protein Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for TP305752 UGT1A6 (NM_205862) Human Recombinant Protein Product data: Product Type: Recombinant Proteins Description: Recombinant protein of human UDP glucuronosyltransferase 1 family, polypeptide A6 (UGT1A6), transcript variant 2 Species: Human Expression Host: HEK293T Tag: C-Myc/DDK Predicted MW: 29.5 kDa Concentration: >50 ug/mL as determined by microplate BCA method Purity: > 80% as determined by SDS-PAGE and Coomassie blue staining Buffer: 25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10% glycerol Preparation: Recombinant protein was captured through anti-DDK affinity column followed by conventional chromatography steps. Storage: Store at -80°C. Stability: Stable for 12 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles. RefSeq: NP_995584 Locus ID: 54578 UniProt ID: Q5DT01 RefSeq Size: 1691 Cytogenetics: 2q37.1 RefSeq ORF: 1599 Synonyms: GNT1; HLUGP; HLUGP1; hUG-BR1; UDPGT; UDPGT 1-6; UGT-1A; UGT-1C; UGT-1E; UGT-1F; UGT1; UGT1-01; UGT1-03; UGT1-05; UGT1-06; UGT1.1; UGT1.3; UGT1.5; UGT1.6; UGT1A; UGT1A1; UGT1A3; UGT1A5; UGT1A6S; UGT1C; UGT1E; UGT1F This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 2 UGT1A6 (NM_205862) Human Recombinant Protein – TP305752 Summary: This gene encodes a UDP-glucuronosyltransferase, an enzyme of the glucuronidation pathway that transforms small lipophilic molecules, such as steroids, bilirubin, hormones, and drugs, into water-soluble, excretable metabolites.
    [Show full text]
  • Complement C3a Signaling Facilitates Skeletal Muscle Regeneration by Regulating Monocyte Function and Trafficking
    ARTICLE DOI: 10.1038/s41467-017-01526-z OPEN Complement C3a signaling facilitates skeletal muscle regeneration by regulating monocyte function and trafficking Congcong Zhang1, Chunxiao Wang1, Yulin Li1, Takashi Miwa2, Chang Liu1, Wei Cui1, Wen-Chao Song2 & Jie Du1 Regeneration of skeletal muscle following injury is accompanied by transient inflammation. Here we show that complement is activated in skeletal muscle injury and plays a key role 1234567890 during regeneration. Genetic ablation of complement C3 or its inactivation with Cobra Venom Factor (CVF) result in impaired muscle regeneration following cardiotoxin-induced injury in mice. The effect of complement in muscle regeneration is mediated by the alternative pathway and C3a receptor (C3aR) signaling, as deletion of Cfb, a key alternative pathway component, or C3aR leads to impaired regeneration and reduced monocyte/macrophage infiltration. Monocytes from C3aR-deficient mice express a reduced level of adhesion molecules, cytokines and genes associated with antigen processing and presentation. Exo- genous administration of recombinant CCL5 to C3aR-deficient mice rescues the defects in inflammatory cell recruitment and regeneration. These findings reveal an important role of complement C3a in skeletal muscle regeneration, and suggest that manipulating complement system may produce therapeutic benefit in muscle injury and regeneration. 1 Beijing AnZhen Hospital, Capital Medical University, The Key Laboratory of Remodeling-related Cardiovascular Diseases, Ministry of Education, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing 100029, China. 2 Department of Pharmacology and Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA 19104, USA. Correspondence and requests for materials should be addressed to W.-C.S.
    [Show full text]
  • Endogenous Protein Interactome of Human UDP-Glucuronosyltransferases Exposed by Untargeted Proteomics
    ORIGINAL RESEARCH published: 03 February 2017 doi: 10.3389/fphar.2017.00023 Endogenous Protein Interactome of Human UDP-Glucuronosyltransferases Exposed by Untargeted Proteomics Michèle Rouleau, Yannick Audet-Delage, Sylvie Desjardins, Mélanie Rouleau, Camille Girard-Bock and Chantal Guillemette * Pharmacogenomics Laboratory, Canada Research Chair in Pharmacogenomics, Faculty of Pharmacy, Centre Hospitalier Universitaire de Québec Research Center, Laval University, Québec, QC, Canada The conjugative metabolism mediated by UDP-glucuronosyltransferase enzymes (UGTs) significantly influences the bioavailability and biological responses of endogenous molecule substrates and xenobiotics including drugs. UGTs participate in the regulation of cellular homeostasis by limiting stress induced by toxic molecules, and by Edited by: controlling hormonal signaling networks. Glucuronidation is highly regulated at genomic, Yuji Ishii, transcriptional, post-transcriptional and post-translational levels. However, the UGT Kyushu University, Japan protein interaction network, which is likely to influence glucuronidation, has received Reviewed by: little attention. We investigated the endogenous protein interactome of human UGT1A Ben Lewis, Flinders University, Australia enzymes in main drug metabolizing non-malignant tissues where UGT expression is Shinichi Ikushiro, most prevalent, using an unbiased proteomics approach. Mass spectrometry analysis Toyama Prefectural University, Japan of affinity-purified UGT1A enzymes and associated protein complexes in liver,
    [Show full text]
  • Immuno-Electron and Confocal Laser Scanning Microscopy of the Glycocalyx
    biology Article Immuno-Electron and Confocal Laser Scanning Microscopy of the Glycocalyx Shailey Gale Twamley 1,2, Anke Stach 1, Heike Heilmann 3, Berit Söhl-Kielczynski 4, Verena Stangl 1,2, Antje Ludwig 1,2,*,† and Agnieszka Münster-Wandowski 3,*,† 1 Medizinische Klinik für Kardiologie und Angiologie, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany; [email protected] (S.G.T.); [email protected] (A.S.); [email protected] (V.S.) 2 DZHK (German Centre for Cardiovascular Research), Partner Site, 10117 Berlin, Germany 3 Institute of Integrative Neuroanatomy, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany; [email protected] 4 Institute for Integrative Neurophysiology—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany; [email protected] * Correspondence: [email protected] (A.L.); [email protected] (A.M.-W.) † These authors equally contributed. Simple Summary: The glycocalyx (GCX) is a hydrated, gel-like layer of biological macromolecules attached to the cell membrane. The GCX acts as a barrier and regulates the entry of external substances into the cell. The function of the GCX is highly dependent on its structure and composition. Citation: Twamley, S.G.; Stach, A.; Pathogenic factors can affect the protective structure of the GCX. We know very little about the three- Heilmann, H.; Söhl-Kielczynski, B.; dimensional organization of the GXC. The tiny and delicate structures of the GCX are difficult Stangl, V.; Ludwig, A.; to study by microscopic techniques.
    [Show full text]
  • The Key to the Nornicotine Enantiomeric Composition in Tobacco Leaf
    University of Kentucky UKnowledge Theses and Dissertations--Plant and Soil Sciences Plant and Soil Sciences 2012 ENANTIOSELECTIVE DEMETHYLATION: THE KEY TO THE NORNICOTINE ENANTIOMERIC COMPOSITION IN TOBACCO LEAF Bin Cai University of Kentucky, [email protected] Right click to open a feedback form in a new tab to let us know how this document benefits ou.y Recommended Citation Cai, Bin, "ENANTIOSELECTIVE DEMETHYLATION: THE KEY TO THE NORNICOTINE ENANTIOMERIC COMPOSITION IN TOBACCO LEAF" (2012). Theses and Dissertations--Plant and Soil Sciences. 5. https://uknowledge.uky.edu/pss_etds/5 This Doctoral Dissertation is brought to you for free and open access by the Plant and Soil Sciences at UKnowledge. It has been accepted for inclusion in Theses and Dissertations--Plant and Soil Sciences by an authorized administrator of UKnowledge. For more information, please contact [email protected]. STUDENT AGREEMENT: I represent that my thesis or dissertation and abstract are my original work. Proper attribution has been given to all outside sources. I understand that I am solely responsible for obtaining any needed copyright permissions. I have obtained and attached hereto needed written permission statements(s) from the owner(s) of each third-party copyrighted matter to be included in my work, allowing electronic distribution (if such use is not permitted by the fair use doctrine). I hereby grant to The University of Kentucky and its agents the non-exclusive license to archive and make accessible my work in whole or in part in all forms of media, now or hereafter known. I agree that the document mentioned above may be made available immediately for worldwide access unless a preapproved embargo applies.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0043923 A1 Parma Et Al
    US 2004.0043923A1. (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0043923 A1 Parma et al. (43) Pub. Date: Mar. 4, 2004 (54) HIGHAFFINITY NUCLEIC ACID LIGANDS on Jun. 5, 1996, which is a continuation-in-part of TO LECTINS application No. 08/479,724, filed on Jun. 7, 1995, now Pat. No. 5,780.228, and which is a continuation (75) Inventors: David H. Parma, Boulder, CO (US); in-part of application No. 08/472,256, filed on Jun. 7, Brian Hicke, Boulder, CO (US); 1995, now Pat. No. 6,001,988, and which is a con Philippe Bridonneau, Boulder, CO tinuation-in-part of application No. 08/472,255, filed (US); Larry Gold, Boulder, CO (US) on Jun. 7, 1995, now Pat. No. 5,766,853, and which is a continuation-in-part of application No. 08/477, Correspondence Address: 829, filed on Jun. 7, 1995, now abandoned, which is SWANSON & BRATSCHUN L.L.C. a continuation-in-part of application No. 07/714, 131, 1745 S.HEA CENTER DRIVE filed on Jun. 10, 1991, now Pat. No. 5,475,096, which SUTE 330 is a continuation-in-part of application No. 07/536, HIGHLANDS RANCH, CO 80129 (US) 428, filed on Jun. 11, 1990, now abandoned. (73) Assignee: GILEAD SCIENCES, INC. Publication Classification (21) Appl. No.: 10/409,627 (51) Int. Cl." ......................... A61K 48/00; A61K 38/16; C12O 1/68 (22) Filed: Apr. 7, 2003 (52) U.S. Cl. ...................................... 514/8; 435/6; 514/44 Related U.S. Application Data (57) ABSTRACT (60) Continuation of application No.
    [Show full text]